Monitoring cell-free DNA in lung cancer patients receiving immunotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to monitor non-small cell lung cancer (NSCLC) patients undergoing immunotherapy by quantifying cell-free DNA (cfDNA) through digital PCR. The primary goal is to evaluate the predictive value of cfDNA levels at the first reevaluation for clinical benefit. Additionally, the study will assess the early predictive value of cfDNA quantification before the second immunotherapy treatment and its correlation with disease progression. This longitudinal approach seeks to establish a robust biomarker for NSCLC treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age over 18
* informed of the objectives of the project and signed consent
* non small cell lung cancer, stage IIIA, IIIB or IV
* PS (WHO performance status) \< or =2
* treatment based on immunotherapy (monotherapy or combination)
* at least one measurable target
* available results of PD-L1 expression

Exclusion Criteria:

* concomitant other type of cancer
* another cancer in the last 5 years

Where it's running

• CHU de Besancon - Service de pneumologie
  Besançon, France Recruiting
• Hopitaux Civils de Colmar - service de Pneumologie
  Colmar, France Recruiting
• CHU de Dijon - service de Pneumologie
  Dijon, France Recruiting
• GHR Mulhouse Sud-Alsace - Service de Pneumologie
  Mulhouse, France Recruiting
• CHU de Reims - service de Pneumologie
  Reims, France Recruiting
• CHRU de Strasbourg
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: BEAU-FALLER Michele, MD
• Email: michele.beau@chru-strasbourg.fr
• Phone: +33 3 88 12 84 57

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Narlumosbart plus targeted bone radiation with chemo‑immunotherapy for advanced non‑small cell lung cancer that has spread to bone

  We will test whether adding narlumosbart (a RANKL‑targeting antibody) and targeted bone radiation to standard first‑line chemo‑immunotherapy helps people with advanced non‑small cell lung cancer that has spread to bone.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06738160

• Fasting-mimicking diet with immunotherapy for advanced non-small cell lung cancer

  This trial will test whether following a fasting-mimicking diet while receiving pembrolizumab helps people with advanced non-small cell lung cancer respond better and have fewer side effects.

  Recruiting at 4 sites VA Office of Research and Development · Long Beach, California and 3 other locations · NCT06671613

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.